Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SanFrancisco99on Mar 15, 2015 7:27pm

302 Views

Post# 23523621

Anyone Else Think This Might Be A Bunch of B and S?

Check out this link: https://www.medpagetoday.com/MeetingCoverage/ACC/50488

You'll see a familiar figure touting the PSCK9 inhibitors.

But wait: Isn't their reduction of events LOWER than that of RVX-208? Plus, their reduction comes at 12-18 months? Ours was at 6 months.

Plus... the drug is an expensive injectable - and one that involves various potential identified risks...!!!

And don't bring up the "post hoc" argument with me. THEIR analysis is post hoc too.

So here's my question for the Board? Am I missing something or is the big PR capabilities of big pharma just being demonstrated again???

Somebody correct me please if I am overlooking something.

Bullboard Posts

MDA Space stock blasts off on Q3 financial results